scholarly journals Capacities of formal methods in objectivization of epileptic severity dynamics

1997 ◽  
Vol XXIX (1-2) ◽  
pp. 30-33
Author(s):  
V. A. Karlov ◽  
P. N. Vlasov ◽  
А. О. Khabibova
Keyword(s):  
Quality Of Life ◽  
Epileptic Seizures ◽  
Severity Scale ◽  
Partial Seizures ◽  
Complex Partial Seizures ◽  
Temporal Epilepsy ◽  
Epileptic Patients ◽  
Therapy Quality ◽  
Index Of Quality

There was analyzed dynamics of morbidity in 65 epileptic patients with the help of severity scale of epileptic seizures, accounting method of recovering percentage, index of quality of life. The highest value on scale was obtained during complex partial seizures, transferring into secondly generalized (15 points), the lowest during typical absentia epileptica (1 point). When mixing some epileptic seizures the total sum of points achieved 34 points. Percentage of improvements was counted in 6 months after correction of therapy. Quality of life was evaluated by 5-point analogue scale, developed by the authors and tested in temporal epilepsy.

Dysembryoplastic Neuroepithelial Tumors

2018 ◽  
Author(s):  
Clayton L. Haldeman ◽  
John S. Kuo
Keyword(s):  
Quality Of Life ◽  
World Health ◽  
Partial Seizures ◽  
Complex Partial Seizures ◽  
Neuroepithelial Tumors ◽  
Dysembryoplastic Neuroepithelial Tumors ◽  
Intractable Seizures ◽  
Clonic Seizures ◽  
Health Organization

Dysembryoplastic neuroepithelial tumors (DNETs) are World Health Organization grade I tumors and have a low potential for malignant transformation. However, DNETs often affect a patient’s quality of life and can cause medically intractable seizures. The estimated prevalence of DNET is 0.6% to .0.8%; however, they are found in approximately 20% of patients undergoing surgery for epilepsy. Greater than 90% of patients with DNET have onset of epilepsy prior to the age of 20. The most common presentations of DNET are complex partial seizures and simple partial seizures. Generalized tonic–clonic seizures are present in about 50% of patients. Patients are often seizure-free after surgical resection.

scholarly journals Outcome Evaluation of Gabapentin as Add-on Therapy for Partial Seizures

1998 ◽  
Vol 25 (2) ◽  
pp. 134-140 ◽  
Author(s):  
Keyword(s):  
Quality Of Life ◽  
Adverse Events ◽  
Adjunctive Therapy ◽  
Positive Impact ◽  
Outcome Evaluation ◽  
Partial Seizures ◽  
Open Label ◽  
Complex Partial Seizures ◽  
Day Range

ABSTRACT:Objective:The safety, tolerability, efficacy, and impact on quality of life of gabapentin (Neurontin®) as adjunctive therapy to carbamazepine (CBZ) and/or phenytoin (PHT) was assessed in epileptic patients with partial seizures.Methods:NEON (Neurontin Evaluation of Outcomes in Neurological Practice) was an open-label, prospective, multicentre study conducted in patients on a stable dose of CBZ and/or PHT and experiencing an average of up to 4 complex partial seizures with or without secondary generalization per month, with no seizure-free months. The treatment lasted 20 weeks. Gabapentin was started at 400 mg/day and was individually titrated to effective tolerable dose up to 2400 mg/day. Quality of life was evaluated using the QOLIE-10 questionnaire.Results:A total of 141 patients were enrolled at 36 sites; 114 patients were evaluable for efficacy analyses. The mean maintenance dose of gabapentin was 1600 mg/day (range = 300-3200). A decrease of 50% or more in frequency of complex partial + secondarily generalized seizures was observed in 81 (71 %) patients (p = 0.0001). Fifty two (46%) patients were seizure-free during the last 8 weeks of treatment. A significant improvement (p < 0.05) was observed in 5 of the 10 questions of the QOLIE-10, as well as in the composite QOL score (p = 0.0002). The most frequent adverse events included somnolence (16%), dizziness (9%), and asthenia (6%). Twenty-five (18%) patients prematurely discontinued the study, 16 (11%) of them due to adverse events.Conclusion:This study indicates that treatment with gabapentin as adjunctive therapy to standard antiepileptic drugs in this group of patients not only provides significant improvement in seizure control, but also has a positive impact on quality of life. The clinical benefits in efficacy, safety and tolerability demonstrated at 20 weeks are sustained, and no tolerance develops with gabapentin in longer term use.

scholarly journals Levetiracetam and Memory Loss

2019 ◽  
Author(s):  
Elham Alshammari
Keyword(s):  
Quality Of Life ◽  
Memory Loss ◽  
Partial Seizures ◽  
Complex Partial Seizures ◽  
Chronic Disorder ◽  
Different Populations ◽  
Treatment Use ◽  
Electrical Activities ◽  
The Brain

Epilepsy is defined as a chronic disorder that causes a sudden rush of electrical activities in the brain. These seizures may be partial or general. While fractional annexations affect a solitary part of the brain, comprehensive seizures distress the entire brain and its activities. There exist myriad options for seizure treatment. Use of Keppra, the brand name for Levetiracetam, is one of the most adopted forms of treatment. These seizures are generally caused by low blood sugar, alcohol withdrawal as well as head trauma. For one to be prescribed seizure drugs, signs such as simple partial seizures, complex partial seizures as well as general seizures must be present. There are other options for managing seizures such as brain surgery, adopting a Ketogenic diet and anti-epileptic drugs. Levetiracetam is typically prescribed as an add-on to these seizure drugs to boost their effectiveness and as well en- sure improved quality of life. While essential resources and information are recommending the use of Levetiracetam, there are also sources discrediting the drug with evidence of causing memory loss and reduced quality of life. Therefore, this study aims at collecting information from different scholarly articles, journals, and websites about the side effects of using Levetiracetam in different populations. After the data is explored, the study offers a comprehensive conclusion based on the information available. The study, therefore, affirms that the use of Levetiracetam improves the quality of life and it does not affect or interfere with the cognitive functions of the brain. The study seeks to demystify the linking of Levetiracetam to memory loss of its users.

scholarly journals Levetiracetam and Memory Loss

2019 ◽  
Vol 10 (2) ◽  
pp. 1249-1253
Author(s):  
Elham Alshammari
Keyword(s):  
Quality Of Life ◽  
Memory Loss ◽  
Partial Seizures ◽  
Complex Partial Seizures ◽  
Chronic Disorder ◽  
Different Populations ◽  
Treatment Use ◽  
Electrical Activities ◽  
The Brain

Epilepsy is defined as a chronic disorder that causes a sudden rush of electrical activities in the brain. These seizures may be partial or general. While fractional annexations affect a solitary part of the brain, comprehensive seizures distress the entire brain and its activities. There exist myriad options for seizure treatment. Use of Keppra, the brand name for Levetiracetam, is one of the most adopted forms of treatment. These seizures are generally caused by low blood sugar, alcohol withdrawal as well as head trauma. For one to be prescribed seizure drugs, signs such as simple partial seizures, complex partial seizures as well as general seizures must be present. There are other options for managing seizures such as brain surgery, adopting a Ketogenic diet and anti-epileptic drugs. Levetiracetam is typically prescribed as an add-on to these seizure drugs to boost their effectiveness and as well ensure improved quality of life. While essential resources and information are recommending the use of Levetiracetam, there are also sources discrediting the drug with evidence of causing memory loss and reduced quality of life. Therefore, this study aims at collecting information from different scholarly articles, journals, and websites about the side effects of using Levetiracetam in different populations. After the data is explored, the study offers a comprehensive conclusion based on the information available. The study, therefore, affirms that the use of Levetiracetam improves the quality of life and it does not affect or interfere with the cognitive functions of the brain. The study seeks to demystify the linking of Levetiracetam to memory loss of its users.

scholarly journals Quality of life and its determinants in patients with drug resistant focal epilepsy

2021 ◽  
Vol 12 (4) ◽  
pp. 216-225
Author(s):  
S. М. Malyshev ◽  
Т. М. Alekseeva
Keyword(s):  
Quality Of Life ◽  
Social Status ◽  
Depressive Disorders ◽  
Focal Epilepsy ◽  
Multiple Linear Regression Model ◽  
Epileptic Seizures ◽  
Drug Resistant ◽  
Severity Scale ◽  
Pronounced Decrease

Objective: to determine the factors influencing quality of life (QoL) in patients with drug-resistant focal epilepsy (DRFE). Material and methods. 111 adult patients with DRFE were included in the study. Quality of life was measured using the Quality Of Life In Patients with Epilepsy – 31 questionnaire (QOLIE-31). The severity of the disease (frequency and subjective assessment of the severity of seizures), the effect of pharmacotherapy (drug load and composition of the treatment regimen), the social status of patients, comorbid conditions (anxiety and depressive disorders, pathological fatigue) were assessed. Results. In the studied sample, a pronounced decrease in QoL was shown, the median of the final QOLIE-31 score was 65.4 points (interquartile range 53.0–72.6 points). A statistically significant decrease in QoL was found in subgroups of patients with seizures during the previous three months; taking carbamazepine or benzobarbital; with anxiety and depressive disorders; with pathological fatigue; and in unemployed patients. A multiple linear regression model (R2=0.66) was developed, which included the following determinants: Fatigue Severity Scale, Liverpool Seizure Severity Scale, and the risk of depression according to the NDDI-E questionnaire. Conclusion. In patients with drug-resistant focal epilepsy, there is a pronounced decrease in the quality of life due to combination of factors associated with the characteristics of the disease, treatment, comorbidities, and social status. The key QoL determinants in patients with DRFE are pathological fatigue, anxiety and depression, and subjective severity of epileptic seizures; employment is a positive factor. The role of epileptic seizures frequency in QoL formation in these patients requires further research.

scholarly journals Epilepsy and quality of life in Iranian epileptic patients

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Bahareh Honari ◽  
Seyed Mehran Homam ◽  
Maryam Nabipour ◽  
Zahra Mostafavian ◽  
Arezou Farajpour ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Negative Relationship ◽  
Well Being ◽  
Subscale Score ◽  
Social Consequences ◽  
Contributing Factors ◽  
Epileptic Patients ◽  
The Mean ◽  
Spss Software

Abstract Background Epilepsy is one of the most common neurological disorders with physical, emotional, and social consequences. Previous studies indicate that epilepsy symptoms can highly affect the epileptic patients’ satisfaction in life. The aim of the present study is to investigate the QOL of People with Epilepsy (PWE) in Khorasan Razavi province, Iran. Methods In this study, 100 patients were randomly selected. After confirmation of the diagnosis of epilepsy by neurologists and fulfilling the entrance criteria, patients completed the Quality of Life in Epilepsy-31 inventory (QOLIE-31) questionnaire. Finally, data was analyzed statistically by SPSS software. Results The study sample comprised 100 PWE, aged 18–74 years (34 ± 13), of whom 58 (58%) were females. Tonic-colonic seizure was the most common (60%) type of seizure. The obtained score of each subscale and the range of the QOLIE-31 total score was 16.40–79.18 with the mean of 50 (SD = 16). The energy-fatigue subscale score was significantly higher in patients younger than 35 (p = 0.018). The data analysis showed that the seizure worry subscale was significantly higher in single patients (p = 0.04). Duration of epilepsy had a positive correlation with QOLIE-31 total score (p = 0.038), and a negative relationship with energy-fatigue subscale (p = 0.018). In contrast with previous studies, which reported the frequency of the epileptic episodes as the most important predictor of QOL, our results showed no significant correlation between the number of the episodes and overall QOL score (p = 0.063). However, the number of episodes was significantly correlated with emotional well-being and cognition subscales. Furthermore, the results indicated that poor QOL score is correlated with depressed mood. Conclusion In fact, the ultimate and preferred outcome of all treatments and care interventions is the patient’s QOL. Thus, improvement of the QOL by means of obtaining more information about its contributing factors, in PWE should be one of the main goals in the patients’ treatment.

Medical technology: A systematic review on medical devices utilized for epilepsy prediction and management

2021 ◽  
Vol 19 ◽  
Author(s):  
Jen Sze Ong ◽  
Shuet Nee Wong ◽  
Alina Arulsamy ◽  
Jessica L. Watterson ◽  
Mohd. Farooq Shaikh
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Medical Devices ◽  
Epileptic Seizures ◽  
Well Being ◽  
Sudden Unexpected Death ◽  
Unexpected Death ◽  
Long Time ◽  
Wearable Medical

: Epilepsy is a devastating neurological disorder that affects nearly 70 million people worldwide. Epilepsy causes uncontrollable, unprovoked and unpredictable seizures that reduces the quality of life of those afflicted, with 1-9 epileptic patient deaths per 1000 patient occurring annually due to sudden unexpected death in epilepsy (SUDEP). Predicting the onset of seizures and managing them may help patients from harming themselves and may improve their well-being. For a long time, electroencephalography (EEG) devices have been the mainstay for seizure detection and monitoring. This systematic review aimed to elucidate and critically evaluate the latest advancements of medical devices, besides EEG, that have been proposed for the management and prediction of epileptic seizures. A literature search was performed on three databases; PubMed, Scopus and EMBASE. Following title/abstract screening by two independent reviewers, 27 articles were selected for critical analysis in this review. These articles revealed ambulatory, non-invasive and wearable medical devices such as the in-ear EEG devices, the accelerometer-based devices and the subcutaneous implanted EEG devices might be more acceptable than traditional EEG systems. In addition, extracerebral signal-based devices may be more efficient than EEG-based systems, especially when combined with an intervention trigger. Although further studies may still be required to improve and validate these proposed systems before commercialization, these findings may give hope to epileptic patients, particularly those with refractory epilepsy, to predict and manage their seizures. The use of medical devices for epilepsy may improve patients' independence and quality of life and possibly prevent sudden unexpected death in epilepsy (SUDEP).

Elucidating the Potential Side Effects of Current Anti- Seizure Drugs for Epilepsy

2021 ◽  
Vol 19 ◽  
Author(s):  
Enes Akyüz ◽  
Mohd. Farooq Shaikh ◽  
Betül Köklü ◽  
Cansu Ozenen ◽  
Alina Arulsamy
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Adverse Effects ◽  
Side Effect ◽  
First Line ◽  
Epileptic Patients ◽  
Life Threatening ◽  
Visual Problems ◽  
Gaba Transmission

: Over the decades, various interventions have been developed and utilized to treat epilepsy. However, majority of epileptic patients are often first prescribed with anti-epileptic drugs (AED), now known as anti-seizure drugs (ASD), as a first line of defense to suppress their seizures and regain their quality of life. ASDs exert their anti-convulsant effects through various mechanisms of action including regulation of ion channels, blocking of glutamate-mediated stimulating neurotransmitter interaction, and enhancing the inhibitory GABA transmission. About one third of epileptic patients are often resistant to anti-convulsant drugs, while others develop numerous side effects which may lead to treatment discontinuation and further deterioration of quality of life. Common side effects of ASDs include headache, nausea and dizziness. However, more adverse effects such as auditory and visual problems, skin problems, liver dysfunction, pancreatitis and kidney disorders may also be witnessed. Some ASDs may even result in life-threatening conditions as well as serious abnormalities, especially in patients with comorbidities and in pregnant women. Nevertheless, some clinicians had observed a reduction in the development of side effects post individualized ASD treatment. This suggest that a careful and well-informed ASD recommendation to patients may be crucial for an effective and side-effect free control of their seizures. Therefore, this review aimed to elucidate the anticonvulsant effects of ASDs as well as their side effect profile, by discussing their mechanism of action and reported adverse effects based on clinical and preclinical studies, thereby providing clinicians with a greater understanding of the safety of current ASDs.

scholarly journals Etiology of epilepsy a prospective study of 210 cases

1991 ◽  
Vol 49 (3) ◽  
pp. 251-254 ◽  
Author(s):  
Walter Oleschko Arruda
Keyword(s):  
Ct Scan ◽  
Neurological Examination ◽  
Epileptic Seizures ◽  
Partial Seizures ◽  
Complex Partial Seizures ◽  
Blood Tests ◽  
Generalized Seizures ◽  
A Prospective Study ◽  
Csf Examination

The objective of this study was to establish the etiology of epilepsy in 210 chronic epileptics (110 female, 100 male), aged 14-82 years (34.2±13.3). Patients less than 10 years-old and alcoholism were excluded. All underwent neurological examination, routine blood tests, EEG and CT-scan. Twenty patients (10.5%) were submitted to spinal tap for CSF examination. Neurological examination was abnormal in 26 (12.4%), the EEG in 68 (45.5%), and CT-scan in 93 (44.3%). According to the International Classification of Epileptic Seizures (1981), 101 (48.1%) have generalized seizures, 66 (31.4%) partial seizures secondarily generalized, 25 (11.8%) simple partial and complex partial seizures, and 14 (6.6%) generalized and partial seizures. Four patients (2.0%) could not be classified. In 125 (59.5%) patients the etiology was unknown. Neurocysticercosis accounted for 57 (27.1%) of cases, followed by cerebrovascular disease 8 (3.8%), perinatal damage 5 (2.4%), familial epilepsy 4 (1.9%), head injury 4 (1.9%), infective 1 (0.5%), and miscelanea 6 (2.8%).

Sign in / Sign up

Export Citation Format

Share Document